Lupin gets USFDA nod for asthma drug

| Updated on November 13, 2018 Published on November 13, 2018

Lupin has received approval for its Budesonide Inhalation Suspension, 0.5 mg/2 mL Single-Dose Ampules from the US Food and Drug Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP’s (AstraZeneca) Pulmicort Respules Inhalation Suspension. Budesonide Inhalation Suspension is indicated for the maintenance treatment of asthma and as prophylactic therapy in children 12 months to 8 years of age. Shares of Lupin closed at ₹853.15, down 0.85 per cent.

Published on November 13, 2018
This article is closed for comments.
Please Email the Editor